Skip to main content

Table 3 Conditions and symptoms treated with cannabis according to gender and age among individuals who reported self-medication with cannabis in an online survey in Quebec from November 2020 to January 2021 (n = 489)

From: A description of self-medication with cannabis among adults with legal access to cannabis in Quebec, Canada

Treated conditions Gender (missing = 3; 16 participants with “other gender” not stratified) Age (years) (missing = 4) Total
Men (n = 233) Women (n = 237) p-value ≤ 34 (n = 251) > 34 (n = 234) p-value
Psychological disorders 199 (85.41) 202 (85.23) 0.96 226 (90.04) 189 (80.77) 0.0037 415 (85.57)
 Anxiety 155 (66.52) 176 (74.26) 0.06 196 (78.09) 148 (63.253) 0.0003 344 (70.93)
 Depression 95 (40.77) 78 (32.91) 0.07 113 (45.02) 71 (30.34) 0.0009 184 (37.94)
 Insomnia 136 (58.37) 129 (54.43) 0.39 148 (58.96) 126 (53.85) 0.25 274 (56.49)
 PTSDa 33 (14.16) 40 (16.88) 0.41 43 (17.13) 34 (14.53) 0.43 77 (15.88)
 ADHDb 75 (32.19) 47 (19.83) 0.002 68 (27.09) 56 (23.93) 0.42 124 (25.57)
 Shyness 38 (16.31) 14 (5.91) 0.0003 43 (17.13) 11 (4.70) < 0.0001 54 (11.13)
Somatic disorders 168 (72.10) 184 (77.64) 0.17 179 (71.31) 182 (77.78) 0.103 361 (74.43)
 Chronic non-cancer pain 126 (54.08) 126 (53.16) 0.84 115 (46.82) 144 (61.54) 0.0005 259 (53.40)
 Headaches/migraines 61 (26.18) 74 (31.22) 0.23 86 (34.26) 52 (22.22) 0.003 138 (28.45)
 Bowel disease 22 (9.44) 33 (13.92) 0.13 20 (7.97) 35 (14.96) 0.015 55 (11.34)
 Muscle spasticity 47 (20.17) 33 (13.92) 0.07 36 (14.34) 45 (19.23) 0.14 81 (16.70)
 Nausea/vomiting (unrelated to chemotherapy) 15 (6.44) 30 (12.66) 0.02 28 (11.16) 20 (8.55) 0.33 48 (9.90)
 Endometriosis or other gynecological disorder NA 36 (15.19) - 27/125 (21.60) 8/112 (7.14) 0.0017 35/237 (14.77)
Unclassified
 Loss of appetite 46 (19.74) 41 (17.30) 0.50 57 (22.71) 35 (14.96) 0.029 92 (18.97)
 Sexual disorder 14 (6.01) 19 (8.02) 0.39 20 (7.97) 13 (5.56) 0.29 33 (6.80)
Other conditionsc 45 (19.31) 32 (13.50) 0.09 31 (12.35) 50 (21.37) 0.0078 81 (16.70)
  1. Comparisons between groups were made using chi-square tests and p-value calculated. A p-value < 0.05 was considered as statistically significant
  2. aPTSD Post-traumatic stress disorder
  3. bADHD Attention deficit hyperactivity disorder
  4. cOther conditions include cancer pain (n = 3), cancer (n = 7), palliative care (n = 1), schizophrenia/psychosis (n = 3), nausea due to chemotherapy, obesity (n = 7), diabetes (n = 8), weight loss (n = 12), alcohol or opioid withdrawal (n = 15), tic disorder/Gilles de la Tourette’s syndrome (n = 3), tremor/Parkinson disease (n = 7), bladder disorder/incontinence (n = 8), asthma (n = 1), autism (n = 1), congestion (n = 1), trigger finger (n = 1), gender dysphoria (n = 1), rash (n = 1), nicotine withdrawal symptom (n = 2), hypothyroidism (n = 1), snoring (n = 1), chronic obstructive pulmonary disease (n = 1), psoriasis (n = 10), Ehlers-Danlos syndrome (n = 1), restless legs syndrome (n = 3), borderline personality disorder (n = 2), shingles (n = 1), suicidal ideation (n = 1), Meniere’s disease (n = ), itchy skin (n = 1), mental/ocular fatigue (n = 1)